Please login to the form below

Not currently logged in
Email:
Password:

WCCT Global talks up orphan drug benefits of new service

CRO's In-Site programme will harness digital technology for patient recruitment

WCCT GlobalContract research organisation WCCT Global says its newly-launched patient recruitment service could have particular application in orphan drug trials.

The California, US-based CRO's new In-Site programme uses digital technology to locate patient groups and determine the best sites to conduct the clinical trial.

WCCT says patient recruitment is often as much of a challenge as the technical and commercial hurdles orphan drugs face, if not more so. 

WCCT Global's chief operating officer Jon Rojas said: "We have established our specialised recruitment method which is uniquely applicable to the recruitment issues faced by sponsors that are developing orphan drugs. We point this out because we feel there is a need in the clinical research industry that must to be filled.”

The In-Site patient recruitment tool focuses on identifying patients that could best fit a particular trial to increase the efficiency of the process. 

The new programme also includes an “advanced digital advertising process”. This entails creating an “in-depth psychographic” based on the orphan indication and then targeting digital and social media outlets in order to ensure patient access.

Article by
Dominic Tyer

26th February 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics